Semaglutide

CAS 910463-68-2 52 API suppliersPeptide

Overview

Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist used for the management of type 2 diabetes and chronic weight management. It stimulates insulin secretion and signals to the brain to reduce appetite and caloric intake.

API suppliers (52)

Suppliers of Semaglutide evidenced by a US FDA Type II Drug Master File or an EU Certificate of Suitability (CEP). Sources: FDA DMF list, EDQM certification database.

Where these suppliers are
China28India5United States2Belgium1Switzerland1Netherlands1

Country recorded for 38 of 52 suppliers.

10 of 52 hold a GMP certificate on record in the EU or UK registers

Showing 25 of 52 suppliers — see the full list in the app.

Patent & exclusivity (US)

Per the FDA Orange Book (28 approved US products), the latest listed US patent on Semaglutide expires 17 Feb 2041 and exclusivity 19 Mar 2029. Generic API sourcing typically opens up once these lapse.

Therapeutic areas

DiabetesWeight ManagementMetabolic Disorders
Verified Supplier Partner

Do you supply Semaglutide? Get in front of buyers actively sourcing it.

We route real sourcing requests from pharma buyers to vetted, verified partners — qualified leads, not just a listing. Tell us what you make and we'll be in touch about becoming a Verified Supplier Partner.

No cost to enquire · we only reach out with a fit.

Ready to Accelerate Your
Discovery Workflow?

Find, vet, and source drug-manufacturing partners faster — with FDA compliance screening built in. Start free for 7 days.